# Immunoediting in Cutaneous Squamous Cell Carcinoma

> **NIH NIH F30** · UNIVERSITY OF ARIZONA · 2023 · $42,097

## Abstract

PROJECT SUMMARY:
Immunosuppressed transplant recipients have a 65-253 fold higher risk of developing cutaneous squamous
cell carcinoma (cSCC) and are contraindicated for treatment with immune checkpoint inhibitors, presenting an
important unmet clinical need. The ability of T cells to constrain cSCC is demonstrated by the response of 32-
46% of immunocompetent patients to immune checkpoint inhibitors. However, cSCC has the potential to evade
an active T cell response as demonstrated by the formation of cSCC in immunocompetent patients and
resistance to immune checkpoint inhibition in some patients. Prior work suggests that evasion of an active T
cell response occurs through the process of immunoediting, in which T cells destroy tumors that present
mutated tumor proteins that bind the T cell receptor (neoantigens), and thus select for less immunogenic
tumors. This proposal will compare the neoantigen profile and immune escape mechanisms in tumors and
tumor-adjacent skin from immunosuppressed and immunocompetent individuals as a novel approach to
evaluate the role of T cells in immunoediting. Evaluating the neoantigen profile in carcinogen-exposed tumor-
adjacent skin will additionally provide evidence for immunoediting before the formation of a clinically apparent
lesion. Furthermore, since cSCC in immunosuppressed patients develops in the context of diminished T cell
function, this proposal tests the innovative concept that these patients will have a neoantigen profile that is
more amenable to treatment with a personalized neoantigen vaccine. The Hastings laboratory has created an
MHC class I neoantigen prioritization model with high accuracy in predicting neoantigens that elicit a T cell
response, which will be applied to evaluate the neoantigen profiles of cSCC from immunosuppressed and
immunocompetent individuals. The Hastings laboratory has also generated and characterized a solar-
simulated light induced, transplantable cSCC tumor that will be used to test vaccine efficacy in the proposed
studies. Preliminary data demonstrate that the cSCC transplantable model is constrained by T cells and
vaccination with irradiated tumor cells protects from tumor challenge. This proposal will test the central
hypothesis that cSCC and carcinogen-exposed, tumor-adjacent skin from immunosuppressed individuals will
have a more immunogenic neoantigen profile and less frequent immune escape mechanisms compared to
cSCC from immunocompetent individuals. Aim 1 of this proposal will compare the neoantigen profile and
immune escape mechanisms between immunosuppressed and immunocompetent patients. Aim 2 will
compare the neoantigen profile and immune escape mechanisms of cSCC from mice with and without a
functional T cell repertoire and demonstrate the efficacy of cancer vaccines in immunosuppressed mice. The
impact of the project is to provide evidence for neoantigen vaccines as an important treatment option for
immunosuppressed patients and systematically characteriz...

## Key facts

- **NIH application ID:** 10676479
- **Project number:** 1F30CA281056-01
- **Recipient organization:** UNIVERSITY OF ARIZONA
- **Principal Investigator:** Elizabeth Borden
- **Activity code:** F30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $42,097
- **Award type:** 1
- **Project period:** 2023-07-01 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10676479

## Citation

> US National Institutes of Health, RePORTER application 10676479, Immunoediting in Cutaneous Squamous Cell Carcinoma (1F30CA281056-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10676479. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*